Table 1.
Group characteristics at baseline and at follow-up year 5 and year 9, including follow-up diagnoses
| Characteristics | Baseline | Follow-up year 5 | Follow-up year 9 |
|---|---|---|---|
| Baseline demographics | |||
| Number (n) | 44 | ||
| Sex (F/M) | 29/15 | ||
| Age (y) | 72 (65–78) | ||
| Education (y) | 11 (9–15) | ||
| APOE ε4 (n) (homo-/heterozygous) | 1/14 | ||
| Follow-up time (mo) | 111 (110–112) | ||
| Cognitive tests | |||
| MMSE (points) | 30.0 (29.0–30.0) | 29.0 (27.0–29.0) | 28.0 (26.0–29.0) |
| AQT (s)∗ | 62.0 (52.5–69.0)† | 61.0 (53.5–74.5) | 67.0 (56.5–84.0) |
| Delayed memory (ADAS), correct words of 10 | 8.0 (7.0–9.0) | 8.0 (7.0–9.0) | 8.0 (6.0–9.0) |
| CSF biomarkers | n = 44 | n = 32 | n = 27‡ |
| Aβ42 | 252.0 (174.5–312.0) | 230.0 (180.5–292.5) | 238.0 (139.0–275.0) |
| T-tau | 67.5 (55.5–92.0) | 74.0 (58.0–99.0) | 79.0 (58.0–111.0) |
| P-tau | 27.0 (21.5–43.5) | 35.0 (21.0–50.0) | 29.0 (22.0–41.0) |
| Follow-up diagnosis, n | n = 44 (53)§ | ||
| Normal | 32 (39) | ||
| Mild cognitive impairment | 4 (5) | ||
| Alzheimer's dementia | 5 (5) | ||
| Lewy body dementia | 1 (1) | ||
| Vascular dementia | 1 (1) | ||
| Other dementia | 1 (1) | ||
Abbreviations: APOE, apolipoprotein E; MMSE, mini-mental state examination; AQT, a quick test; ADAS, Alzheimer's disease assessment scale; CSF, cerebrospinal fluid; Aβ42, β-amyloid 42; T-tau, total tau; P-tau, phosphorylated tau.
NOTE. Median values with 25th–75th interquartile range within brackets.
Color-form version of AQT is stated (reference value <70 s).
AQT was not performed at baseline and, therefore, values from follow-up year 3 are given.
Not all have CSF measurement from year 5, which results in 36 participants with two CSF assessments and 23 participants with all three CSF assessments. CSF levels are given in ng/L.
Numbers within brackets include premortem diagnosis for participants who deceased during follow-up and that were included in the Cox regression model.